Annovis Bio Appoints Hui Liu as Director of Biostatistics

Rhea-AI Summary

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative disorders, has appointed Hui Liu as Director of Biostatistics. This strategic hire comes as the company advances its pivotal Phase 3 Alzheimer's disease trial.

Ms. Liu brings over 19 years of experience in clinical trial statistics, specializing in:

• Design and analysis of all clinical trial phases
• Statistical methodology expertise
• Development of statistical analysis plans
• Management of high-performing teams

According to Dr. Cheng Fang, Senior VP of Research and Development, Liu's appointment strengthens the company's scientific excellence and will support data integrity for regulatory submissions. The new Director expressed enthusiasm about joining Annovis's team and contributing to their clinical trials' quality evidence generation.

Positive

• Strengthens clinical data analysis capabilities with experienced biostatistics hire for Phase 3 AD trial
• New director brings 19 years of experience in clinical trials and regulatory submissions
• Strategic hire aligns with late-stage development of Alzheimer's and Parkinson's treatments

Negative

• None.

News Market Reaction – ANVS

-5.16%

1 alert

-5.16% News Effect

On the day this news was published, ANVS declined 5.16%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the appointment Hui Liu as Director of Biostatistics.

“Bringing Ms. Liu on board at this critical stage, as our pivotal Phase 3 AD trial advances, reinforces our commitment to scientific excellence,” said Cheng Fang, Ph.D., Senior Vice President, Research and Development. “Her statistical expertise will help ensure the integrity of our data and support robust regulatory submissions as we move toward our goals.”

Ms. Liu has over 19 years of experience in design, analysis, and reporting all phases of clinical trials across a broad range of therapeutic areas. She brings deep expertise in statistical methodology, including authoring statistical analysis plans, developing programming specifications, and interpreting complex data to support regulatory submissions. In addition to her technical strengths, Ms. Liu has led high-performing teams, managed large accounts, and driven strategic initiatives with a focus on quality, efficiency, and collaboration.

"I’m excited to join Annovis and honored to work with a passionate and driven team,” commented Ms. Liu. “I look forward to applying my statistical expertise to further enhance the integrity of the company’s clinical trials and to help generate high-quality evidence that will support scientific advancement and regulatory success.”

About Annovis

Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements

This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

What role will Hui Liu play at Annovis Bio (ANVS) in 2025?

Hui Liu will serve as Director of Biostatistics at Annovis Bio, bringing 19 years of clinical trial experience to oversee statistical analysis for the company's Phase 3 Alzheimer's disease trial.

How does Hui Liu's appointment impact ANVS Phase 3 Alzheimer's trial?

Liu's statistical expertise will help ensure data integrity and support robust regulatory submissions for ANVS's pivotal Phase 3 Alzheimer's disease trial, strengthening the company's scientific capabilities.

What experience does Hui Liu bring to Annovis Bio (ANVS)?

Hui Liu brings 19 years of experience in clinical trial design, analysis, and reporting across multiple therapeutic areas, with expertise in statistical methodology and leading high-performing teams.

Which neurodegenerative diseases is Annovis Bio (ANVS) targeting?

Annovis Bio is developing treatments for neurodegenerative disorders, specifically focusing on Alzheimer's disease (AD) and Parkinson's disease (PD).

What stage is Annovis Bio (ANVS) in their drug development process?

Annovis Bio is currently in the late-stage clinical development phase, conducting a pivotal Phase 3 trial for Alzheimer's disease treatment.